AWKN — Awakn Life Sciences Income Statement
0.000.00%
Last trade - 00:00- CA$6.56m
- CA$6.01m
- CA$1.50m
Annual income statement for Awakn Life Sciences, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0.236 | 1.5 |
| Cost of Revenue | |||
| Gross Profit | 0 | -0.277 | -1.55 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 1.1 | 11.2 | 11.5 |
| Operating Profit | -1.1 | -11 | -10 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -1.11 | -16.5 | -9.65 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -1.11 | -16.5 | -9.65 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | -0.945 | -15.9 | -9.14 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.945 | -15.9 | -9.14 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.019 | -0.673 | -0.329 |
| Dividends per Share |